submit to the journals

Risk Scores for Predicting Post-thrombolysis Intracerebral Hemorrhage

US Neurology, 2010;5(2):39-40 DOI: http://doi.org/10.17925/USN.2010.05.02.39

Abstract:

Post-thrombolysis hemorrhage is a major concern for physicians treating acute ischemic stroke. Two scoring systems that incorporate factors associated with post-thrombolysis hemorrhage have been developed in an attempt to estimate the risk of developing post-thrombolysis hemorrhage among stroke patients. In this article we discuss these scoring systems and their utility in the clinical assessment of stroke patients.
Keywords: Stroke, recombinant tissue plasminogen activator (rt-PA), thrombolysis, hemorrhage, symptomatic intracerebral hemorrhage, risk score
Disclosure: The authors have no conflicts of interest to declare.
Received: February 11, 2009 Accepted: July 14, 2009
Correspondence: Brett Cucchiara, MD, Department of Neurology, Hospital of the University of Pennsylvania, 3400 Spruce Street, 3 West Gates Building, Philadelphia, PA 19104. E: cucchiar@mail.med.upenn.edu

Intracerebral hemorrhage (ICH) is the most dangerous and dreaded complication of thrombolytic therapy for acute ischemic stroke (AIS). The risk for symptomatic ICH (SICH) after AIS was increased from 0.6 to 6.4% after treatment with recombinant tissue plasminogen activator (rt-PA) compared with placebo in the National Institute of Neurological Disorders and Stroke (NINDS) trial.1 Despite this increased risk for ICH, treatment with rt-PA was associated with significantly better clinical outcomes at three months and one year after stroke.1,2 These results led to approval of rt-PA by the US Food and Drug Administration (FDA) for the treatment of AIS in 1996. Almost two decades after the NINDS trial reported the benefit of thrombolytic therapy, fewer than 5% of stroke patients receive rt-PA despite aggressive community and physician education.3 While there are several factors limiting its utility, fear surrounding hemorrhagic complications has undoubtedly played a significant role in limiting the clinical use of rt-PA.

Definitions of Post-thrombolysis Intracerebral Hemorrhage

Post-thrombolysis ICH can be classified based on radiographic criteria alone or on the combination of a clinical change in a patient’s neurological status in conjunction with evidence of ICH on brain imaging studies. Both approaches have strengths and weaknesses. Use of a classification scheme incorporating clinical changes (i.e. symptomatic versus asymptomatic ICH) is subject to imprecision given the fact that observed neurological changes may or may not be causally related to visualized ICH, and the criteria used to establish a change in neurological status may be variable. On the other hand, ICH associated with neurological deterioration (SICH) may be most relevant to patients and physicians as this is directly related to an observable clinical change. Radiographic criteria for defining ICH may be more objective and reliable, but may have less direct clinical relevance.

At present, the most common radiographic classification scheme divides post-thrombolysis ICH into hemorrhagic infarction (HI) and parenchymal hemorrhage (PH).4 In the NINDS trial, HI was defined as punctuate or patchy hyperdensity with an indistinct border, and PH was described as a hyperdensity with a sharply demarcated border with or without edema or mass effect.1 The European Cooperative Acute Stroke Study (ECASS) further expanded this scheme, with the subclasses of HI1 for small petechiae at the borders of an infarct, HI2 for confluent petechiae without mass effect within an infarct, PH1 for hematomas occupying <30% of the infarct with mass effect, and PH2 for hemorrhages occupying >30% of the infarcted territory with mass effect.5,6 PH, and in particular PH2, has been shown to worsen clinical outcomes.7–9

References:
  1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, Tissue plasminogen activator for acute ischemic stroke, N Engl J Med, 1995;333:1581–7.
  2. Kwiatkowski TG, Libman RB, Frankel M, et al., Effects of tissue plasminogen activator for acute ischemic stroke at one year, N Engl J Med, 1999;340:1781.
  3. Douglas VC, Tong DC, Gillum LA, et al., Do the Brain Attack Coalition’s criteria for stroke centers improve care for ischemic stroke?, Neurology, 2005;64(3):422–7.
  4. Pessin MS, Del Zoppo GJ, Estol CJ, Thrombolytic agents in the treatment of stroke, Clin Neuropharmacol, 1990;13(4): 271–89.
  5. Hacke W, Kaste M, Fieschi C, et al., Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS), JAMA, 1995;274(13):1017–25.
  6. Hacke W, Kaste M, Fieschi C, et al., Randomised doubleblind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II), Lancet, 1998;352:1245–51.
  7. Fiorelli M, Bastianello S, von Kummer R, et al., Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort, Stroke, 1999;30(11):2280–84.
  8. Berger C, Fiorelli M, Steiner T, et al., Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic?, Stroke, 2001;32(6):1330–35.
  9. Trouillas P, von Kummer R, Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke, Stroke, 2006;37(2):556–61.
  10. Hacke W, Kaste M, Bluhmki E, et al., Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke, N Engl J Med, 2008;359(13):1317–29.
  11. Wahlgren N, Ahmed N, Davalos A, et al., Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study, Lancet, 2007;369(9558): 275–82.
  12. Lansberg MG, Albers GW, Wijman CA, Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors, Cerebrovasc Dis, 2007;24(1):1–10.
  13. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group, Stroke, 1997;28(11):2109–18.
  14. Demchuk AM, Morgenstern LB, Krieger DW, et al., Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke, Stroke, 1999;30(1):34–9.
  15. Jaillard A, Cornu C, Durieux A, et al., Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group, Stroke, 1999;30(7):1326–32.
  16. Barber PA, Demchuk AM, Zhang J, Buchan AM, Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score, Lancet, 2000;355(9216):1670–74.
  17. Dubey N, Bakshi R, Wasay M, Dmochowski J, Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke, J Neuroimaging, 2001;11(2):184–8.
  18. Kase CS, Furlan AJ, Wechsler LR, et al., Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial, Neurology, 2001;57(9):1603–10.
  19. Larrue V, von Kummer RR, Muller A, Bluhmki E, Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II), Stroke, 2001;32(2):438–41.
  20. Tanne D, Kasner SE, Demchuk AM, et al., Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey, Circulation, 2002;105(14):1679–85.
  21. Hill MD, Buchan AM, Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study, CMAJ, 2005;172(10):1307–12.
  22. Cocho D, Borrell M, Marti-Fabregas J, et al., Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator, Stroke, 2006;37(4):996–9.
  23. Gilligan AK, Markus R, Read S, et al., Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke, Stroke, 2002;33(9):2236–42.
  24. Ribo M, Montaner J, Molina CA, et al., Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator, Stroke, 2004;35(9):2123–7.
  25. Uyttenboogaart M, Koch MW, Koopman K, et al., Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke, Arch Neurol, 2008;65(5):607–11.
  26. Wahlgren N, Ahmed N, Eriksson N, et al., Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST), Stroke, 2008;39(12): 3316–22.
  27. Bang OY, Saver JL, Liebeskind DS, et al., Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis, Neurology, 2007;68(10):737–42.
  28. Selim M, Fink JN, Kumar S, et al., Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume, Stroke, 2002;33(8):2047–52.
  29. Marti-Fabregas J, Bravo Y, Cocho D, et al., Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials, Cerebrovasc Dis, 2007;23(2–3):85–90.
  30. Hacke W, Donnan G, Fieschi C, et al., Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials, Lancet, 2004;363(9411):768–74.
  31. Lou M, Safdar A, Mehdiratta M, et al., The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis, Neurology, 2008;71(18):1417–23.
  32. Cucchiara B, Tanne D, Levine SR, et al., A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke, J Stroke Cerebrovasc Dis, 2008;17(6):331–3.
  33. Castellanos M, Sobrino T, Millan M, et al., Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study, Stroke, 2007;38(6):1855–9.
  34. Warach S, Latour LL, Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption, Stroke, 2004;35(11 Suppl. 1):2659–61.
Keywords: Stroke, recombinant tissue plasminogen activator (rt-PA), thrombolysis, hemorrhage, symptomatic intracerebral hemorrhage, risk score